Iqvia reports Q2 EPS $2.43, consensus $2.37

Reports Q2 revenue $3.73B , consensus $3.70B. As of June 30 R&DS contracted backlog, including reimbursed expenses, was $28.4 billion, growing 11.1 percent year-over-year and 10.8 percent at constant currency. The company expects approximately $7.3 billion of this backlog to convert to revenue in the next twelve months. The second-quarter book-to-bill ratio was 1.28x. For the twelve months ended June 30 , the book-to-bill ratio was 1.34x. “IQVIA continues to execute well in a challenging macro environment, delivering another quarter of strong operational and financial results,” said Ari Bousbib, chairman and CEO of IQVIA. “Clients on the commercial side remain cautious and spending has not accelerated yet. The clinical business is resilient and performing consistently with our expectations. Industry fundamentals are strong, as reflected in our $2.7B of bookings in the quarter and new record highs for RFP flow and backlog.”